WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Permanent URI for this collectionhttps://hdl.handle.net/11147/7150
Browse
65 results
Search Results
Now showing 1 - 10 of 65
Article Citation - WoS: 3Citation - Scopus: 3Her2-Specific Peptide (ltvspwy) and Antibody (herceptin) Targeted Core Cross-Linked Micelles for Breast Cancer: a Comparative Study(MDPI, 2023) Bayram, N.N.; Ulu, G.T.; Abdulhadi, N.A.; Gürdap, S.; İşoğlu, İ.A.; Baran, Yusuf; İşoğlu, S.D.This study aims to prepare a novel breast cancer-targeted micelle-based nanocarrier, which is stable in circulation, allowing intracellular drug release, and to investigate its cytotoxicity, apoptosis, and cytostatic effects, in vitro. The shell part of the micelle is composed of zwitterionic sulfobetaine ((N-3-sulfopropyl-N,N-dimethylamonium)ethyl methacrylate), while the core part is formed by another block, consisting of AEMA (2-aminoethyl methacrylamide), DEGMA (di(ethylene glycol) methyl ether methacrylate), and a vinyl-functionalized, acid-sensitive cross-linker. Following this, a targeting agent (peptide (LTVSPWY) and antibody (Herceptin®)), in varying amounts, were coupled to the micelles, and they were characterized by 1H NMR, FTIR (Fourier-transform infrared spectroscopy), Zetasizer, BCA protein assay, and fluorescence spectrophotometer. The cytotoxic, cytostatic, apoptotic, and genotoxic effects of doxorubicin-loaded micelles were investigated on SKBR-3 (human epidermal growth factor receptor 2 (HER2)-positive) and MCF10-A (HER2-negative). According to the results, peptide-carrying micelles showed a higher targeting efficiency and better cytostatic, apoptotic, and genotoxic activities than antibody-carrying and non-targeted micelles. Also, micelles masked the toxicity of naked DOX on healthy cells. In conclusion, this nanocarrier system has great potential to be used in different drug-targeting strategies, by changing targeting agents and drugs. © 2023 by the authors.Article Citation - WoS: 25Citation - Scopus: 38Biodiversity: the Overlooked Source of Human Health(Elsevier, 2023) Linhares, Yuliya; Kaganski, Alexander; Agyare, Christian; Aksan Kurnaz, Işıl; Neergheen, Vidushi; Kolodziejczyk, Bartlomiej; Baran, YusufBiodiversity is the measure of the variation of lifeforms in a given ecological system. Biodiversity provides ecosystems with the robustness, stability, and resilience that sustains them. This is ultimately essential for our survival because we depend on the services that natural ecosystems provide (food, fresh water, air, climate, and medicine). Despite this, human activity is driving an unprecedented rate of biodiversity decline, which may jeopardize the life-support systems of the planet if no urgent action is taken. In this article we show why biodiversity is essential for human health. We raise our case and focus on the biomedicine services that are enabled by biodiversity, and we present known and novel approaches to promote biodiversity conservation.Conference Object Cytotoxic Effects of Apigenin on Multiple Myeloma Cells(Ferrata Storti Foundation, 2013) Baran, Yusuf; Yılmaz, S.; Cincin, Zeynep; Kozanoğlu, İlknur; Çakmakoğlu, Bedia; Özdoğu, Hakan[No abstract available]Conference Object Changes in Gene Expression Profiles in Response To Apigenin in Imatinib Sensitive and Resistant Chronic Myeloid Leukemia Cells(FERRATA STORTI FOUNDATION, 2013) Baran, Yusuf; Gökbulut, Aysun; Cincin, Zeynep; Çakmakoğlu, Bedia; Kozanoğlu, İlknur[No abstract available]Conference Object Determination of Cytotoxic and Apoptotic Effects of Caffeic Acid Phenethyl Ester and Gossypol in Combination With Fludarabine at a Molecular Level in Acute Lymphoblastic Leukemia Cells(Ferrata Storti Foundation, 2013) Baran, Yusuf; İskender, G.; Pişkin, Özden; Özcan, Mehmet Ali[No abstract available]Conference Object Diagnostic and Therapeutic Potentials of Expression Levels of Bioactive Sphingolipid Genes in Newly Diagnosed and Drug-Resistant Chronic Myeloid Leukemia Patients(Ferrata Storti Foundation, 2013) Baran, Yusuf; Yandım, Melis; Kozanoğlu, İlknur; Özdoğu, Hakan; Pişkin, Özden; Özcan, Mehmet Ali[No abstract available]Conference Object Immunologically Detection of Bcr/Abl Fusion Protein With Flow Cytometry in K562 Chronic Myeloid Leukemia Cells and Comparison With Rt-Pcr Results(Ferrata Storti Foundation, 2013) Kozanoğlu, İlknur; Aygün, B.; Boğa, I.; Cansun, C.; Üstündağ, N.; Baran, Yusuf; Özdoğu, Hakan[No abstract available]Conference Object Comparison of Ishage-Based Cd34 (+) Cell Enumeration Protocols on Bd Facs Canto Iı and Attune Flow Cytometers(Nature Publishing Group, 2014) Kozanoğlu, İlknur; Ünver, Gülşah; Sarıtürk, Çağla; Baran, Yusuf; Yeral, Mahmut; Boğa, Can; Özdoğu, Hakan[No abstract available]Conference Object Effects of Apigenin on Imatinin-Sensitive and Resistant Chronic Myeloid Leukemia Cells(Ferrata Storti Foundation, 2013) Baran, Yusuf; Solmaz, Soner; Gökbulut, Aysun; Kozanoğlu, İlknur; Özdoğu, Hakan[No abstract available]Conference Object Citation - WoS: 1A Study of Multiple Drug Resistance Mechanisms Improved Against Bortezomib on Multiple Myeloma Cell Lines in Vitro(American Society of Hematology, 2007) Uyuklu, Tolga; Ural, A. Uğur; Sarper, Metal; Avcu, Ferit; Baran, Yusuf; Elçi, Pınar; Akar, NejatThe most important problem in the treatment of Multiple Myeloma (MM) is the multi drug resistance (MDR) observed before and after the treatment. For this reason in MM cases an early resistance to treatment can be developed or the disease can relapsed in early period. Yet, there has been no improved drug resistance against proteazom inhibitor Bortezomib (Bor), which is used alone or with other chemotherapeutic agents in resistant or relapsed MM cases